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Abstract
Mesenchymal stromal cells (MSCs) are multipotent 
and self-renewing cells that reside essentially in the 
bone marrow as a non-hematopoietic cell population, 
but may also be isolated from the connective tissues 
of most organs. MSCs represent a heterogeneous 
population of adult, fibroblast-like cells characterized 
by their ability to differentiate into tissues of mesoder-
mal lineages including adipocytes, chondrocytes and 
osteocytes. For several years now, MSCs have been 
evaluated for their in vivo  and in vitro  immunomodula-
tory and ‘tissue reconstruction’ properties, which could 
make them interesting in various clinical settings, and 
particularly in organ transplantation. This paper aims 
to review current knowledge on the properties of MSCs 
and their use in pre-clinical and clinical studies in solid 
organ transplantation, and particularly in the field of 
liver transplantation. The first available clinical data 
seem to show that MSCs are safe to use, at least in the 
medium-term, but more time is needed to evaluate the 
potential adverse effects of long-term use. Many issues 
must be resolved on the correct use of MSCs. Intensive 
in vitro  and pre-clinical research are the keys to a bet-
ter understanding of the way that MSCs act, and to 
eventually lead to clinical success.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: For several years now, mesenchymal stromal 
cells (MSC) have been evaluated for their in vivo  and 
in vitro  immunomodulatory and ‘tissue reconstruction’ 
properties which could make them interesting in vari-
ous clinical settings, and particularly in organ transplan-
tation. This paper aims to review current knowledge 
on the properties of MSCs and their use in pre-clinical 
and clinical studies, and particularly in the field of liver 
transplantation.
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TOPIC HIGHLIGHT
INTRODUCTION
Mesenchymal stromal cells (MSCs) are multipotent and 
self-renewing cells that reside essentially in the bone mar-
row as a non-hematopoietic cell population. MSCs repre-
sent a heterogeneous population of  adult, fibroblast-like 
cells characterized by their ability to differentiate into tis-
sues of  mesodermal lineages including adipocytes, chon-
drocytes and osteocytes. In addition to the bone marrow, 
MSCs have been isolated from various other tissues such 
as adipose tissue[1], skin[2], heart and spleen[3], placenta[4], 
umbilical cord blood[5] as well as lung and liver[6,7], and 
it appears that MSCs reside in the connective tissues of  
most organs[8]. 
No specific marker for MSCs has yet been found. 
Presently, MSCs are identified using a number of  features 
defined by the International Society for Cellular Therapy 
which states three minimal criteria[9]: (1) adhesion to 
plastic in standard culture conditions; (2) expression of  
CD105, CD73 and CD90, and lack of  expression of  
CD45, CD34, CD14 or CD11b, CD79a or CD19 and 
Human Leukocyte Antigen (HLA)-DR surface molecules; 
and (3) in vitro differentiation into osteoblasts, adipocytes 
and chondroblasts.
For several years now, MSCs have been evaluated for 
their in vivo and in vitro immunomodulatory and “tissue 
reconstruction” properties that could make them inter-
esting in various clinical settings such as organ transplan-
tation. This paper aims to review current knowledge on 
the properties of  MSCs and their use in pre-clinical and 
clinical studies in solid organ transplantation, and particu-
larly in the field of  liver transplantation. 
IMMUNOMODULATORY EFFECTS OF 
MSCS
A large number of  in vitro and in vivo studies have docu-
mented the anti-inflammatory and immunoregulatory 
properties of  MSCs on both the adaptive and innate 
immune system. However, there is strong evidence that 
MSCs are not constitutively immunosuppressive, they 
have to be “activated” or primed by local inflammatory 
conditions. Tumor necrosis factor (TNF)-α, interleukin 
(IL)-1β and interferon (IFN)-γ are the key cytokines to 
allow MSC immunomodulation by regulating their immu-
nophenotype[10,11]. The high dependence on environment 
settings could also explain conflicting data in some in vitro 
and in vivo studies. These settings must be further studied 
and considered in clinical trials.
MSC immunogenicity
Both human MSCs (hMSCs) and murine MSCs (mMSCs) 
show low immunogenicity and do not lead to alloreac-
tive T lymphocyte-mediated immune response in vitro. 
Indeed, under normal conditions, MSC membranes 
express low levels of  human leukocyte antigen (HLA) 
class Ⅰ molecules and do not express HLA class Ⅱ (major 
histocompatibility complex (MHC)-Ⅱ) nor co-stimulato-
ry molecules[12,13]. MSCs were thus considered as immune 
privileged cells. However, more recent data with mMSCs 
has suggested that MHC-I on MSCs could present an-
tigen to CD8+ T cells[14]. In addition, a narrow window 
of  IFN-γ could induce MSCs to upregulate MHC-I and 
MHC-Ⅱ and thus, induces an “antigen presenting cell-
like” function. This finding has been observed with both 
mMSCs and hMSCs[10,15-17]. Furthermore, it has been 
demonstrated in an animal model of  bone marrow[18] and 
skin transplantation[19] that donor-derived MSCs could be 
immunogenic and could promote graft rejection.
MSC interaction with immune cells
It is important to highlight that, in some experimental 
conditions, effects of  mMSCs and hMSCs have been 
evaluated on murine immune cells. Results are not always 
transposable to human clinical conditions, especially as 
it is well known that tolerance is more easily achieved in 
animal models than in humans.
It has been demonstrated in vitro and in vivo, that 
MSCs may exert their immunomodulatory effects by act-
ing on many types of  immune cells including T cells, B 
cells and natural killer (NK) cells. The ability of  MSCs 
to inhibit T cell proliferation has been shown in various 
experimental settings both with mMSCs and hMSCs. In 
vitro, hMSCs highly inhibit proliferation and cytokine pro-
duction[20] as well as the development of  human cytotoxic 
CD8+ T cells in mixed-lymphocyte reactions (MLRs)[21,22]. 
Moreover, it has been observed that MSCs promote hu-
man T cell anergy and inhibit alloreactive T cells through 
a TH2 pathway[23]. Nevertheless, it appears that the effect 
of  MSCs on T cells is dependent on the dose used. While 
a high MSC/T cell ratio exert strong inhibitory effects, 
low MSC/T cell ratios enhance T cell proliferation[24].
MSC-induced T-regulatory (T-reg) cell recruitment 
and generation probably play an important role in MSC-
mediated immunomodulatory effects. This has been ob-
served both in vitro[25,26] and in vivo[27,28] both on murine and 
human immune cells. Additionally, previous studies have 
shown that T-reg induced production requires cell con-
tact and some MSC released factors such as prostaglan-
din (PG)-E2 and tumor growth factor (TGF)-β1[29] or 
HLA-G[30,31]. It has been suggested that this effect could 
also be partially mediated by an interaction between MSC 
chemokine (c-c motif) ligand 1 (CCL1) and its receptor 
on T cells, chemokine (c-c motif) receptor 8 (CCR8)[23]. 
More recently, it has been demonstrated that mMSCs 
could promote T-reg expansion by their effects on imma-
ture dendritic cells[32]. 
Published results on the effects of  hMSCs on B cells 
and NK cells are contradictory. Some studies have dem-
onstrated that MSCs could inhibit the proliferation and 
immunoglobulin secretion of  B cells[33-35] while others 
have found no effect of  MSCs on human B cell prolifera-
tion[11,21]. Some researchers have even found that MSCs 
could stimulate human B cell proliferation and antibody 
secretion[36,37]. MSCs have shown an ability to inhibit the 
proliferation of  IL-2 or IL-15 stimulated human NK 
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cells[38,39] and their IFN-γ production[38]. The effects of  
MSCs on the cytotoxic activity of  NK cells are even more 
controverted. While some studies failed to find such an 
effect[40] (especially in freshly isolated NK cells[41]), oth-
ers have demonstrated that MSCs could inhibit NK-cell 
cytotoxicity[30,39]. As MSCs express HLA-1 antigens, even 
at a low level, it appears that they may be vulnerable to 
activated NK-cell lysis[42]. 
Many studies have shown that MSCs can prevent the 
differentiation, maturation and functions of  antigen-pre-
senting cells (APCs), such as human or murine dendritic 
cells (DC)[17,43,44], and thus indirectly modulate T and B 
cell functions. In addition, it was shown that mMSCs may 
induce murine mature DC into a Jagged-2-dependent 
regulatory DC population[45]. MSCs may also exert effects 
on innate immune cells, for example through increased 
IL-10 secretion by macrophages in mice[46].
Mechanisms
The mechanisms of  immunosuppression by MSCs re-
main unclear. Whereas MSCs exert their effect by direct 
cell contact via the expression of  adhesion molecules, it 
has also been shown that the immunomodulatory and 
anti-inflammatory properties of  MSCs mainly involve 
the production of  secreted soluble factors. It has been 
observed that MSCs are still immunosuppressive without 
cell contact[22]. It should be noted that the mechanisms of  
MSC-mediated immunosuppression seems to vary from 
one species to another[47].
Indoleamine 2,3-dioxygenase (IDO) is an enzyme 
that catalyses the degradation of  tryptophan. The result-
ing depletion of  tryptophan and the accumulation of  
its metabolites have shown strong inhibitory properties 
on immune cells, including human T cells[48], activated 
B cells[11] and NK cells[39]. MSCs do not constitutively 
express IDO, but IDO can be upregulated under inflam-
matory conditions, for example after exposure to IFN-γ, 
TNF-α and IL-1[47,48]. IDO could play an important role 
regarding transplantation given that it has been shown 
to partially inhibit allo-responses of  T cells in vitro, and 
to enhance tolerance towards the graft and allogeneic T 
cell transfer in vivo[49,50]. IDO seems to be predominant in 
human MSC-mediated immunomodulatory properties[47]. 
However IDO does not seem to be the only mechanism 
implicated as in some conditions where MSCs do not 
express IDO they keep their immunomodulatory prop-
erties[51]. A high concentration of  nitric oxide (NO) is 
known to inhibit the immune response in both in vitro 
and in vivo studies. It has been shown to inhibit the pro-
liferation of  T cells in murine models. NO is synthetized 
by the inducible NO synthase (iNOS) that is induced in 
murine MSCs by interaction with CD4+ or CD8+ lym-
phocytes in inflammatory conditions involving IFN-γ 
and TNF-α or IL-1[52,53]. As in the case of  IDO for hu-
man MSCs, iNOS appears to play a major role in murine 
MSC-mediated immunomodulation[47,52]. Both tryptophan 
depletion and NO are expected to have an exclusively lo-
cal action[54,55].
The HLA-G protein is a non-classical human MHC-I 
molecule. Initially found in trophoblasts, where it plays a 
crucial role in maternal-fetal tolerance[56], HLA-G has re-
cently been involved in immunomodulation by MSCs[57]. 
HLA-G has shown tolerogenic properties inter alia due 
to its interactions with inhibitory receptors on dendritic 
cells, NK, and T cells. Selmani et al[30] have demonstrated 
that hMSCs, by secreting the soluble isoform HLA-G5, 
are capable of  inhibiting human allo-activated T lympho-
cytes, NK-cell cytolysis and IFN-gamma secretion, and 
of  promoting the expansion of  CD4+CD25highFoxP3+ 
regulatory T cells. Likewise, HLA-G can promote 
CD3+CD4low and CD3+ CD8low immunosuppressive T 
cells. It seems that HLA-G expression is IL-10-dependent 
and needs close cell contact with alloreactive T cells[30]. 
It has been suggested that co-injection of  HLA-G and 
MSCs could be used to prevent rejection in organ trans-
plantation.
Another candidate mechanism involves the role of  
PGE2 (Prostaglandin E2) secreted by MSCs. It appears 
that MSC-derived PGE2 is involved in MSC-mediated 
immunomodulation by acting on murine and human 
T cells (in both TH1 and TH2 responses), NK cells and 
macrophages[46,58]. Prostaglandins have a short half-life. 
This suggests that they play their role using a paracrine 
or autocrine action mechanism. Furthermore, it has been 
observed in human MSCs that IDO and PGE2 have a 
synergistic inhibitory effect on T cell proliferation, and 
on the proliferation and cytotoxicity of  NK cells[39,59]. 
However, other studies suggest that PGE2 could in fact 
have an immunostimulatory role by facilitating TH1 cell 
differentiation and TH17 cell expansion[60].
IL-10 plays an important role in MSC-mediated im-
munosuppression through the induction of  IL-10 pro-
duction in APCs[61]. Nevertheless, no direct secretion of  
IL-10 by MSCs has yet been proven. 
Blocking each of  these factors alone does not restore 
immune cell function and proliferation, indicating that 
multiple factors are involved. 
Other factors are also secreted: TGF-β and Hepato-
cyte growth factor (HGF)[20] (inhibition T-lymphocyte 
proliferation), IL-1 receptor Antagonist[62] (anti-inflam-
matory), Peptide LL-37[63] (anti-inflammatory and anti-
bacterial), Matrix Metalloproteinase (MMP) 3, MMP9[64] 
(acting on neoangiogenesis), angiopoietin-1[65] (acting on 
protein permeability). TNF-α and insulin-like growth 
factor-binding proteins[51] also seem to be implicated. 
On the other hand, MSCs also have the ability to 
secrete pro-inflammatory chemokines and cytokines, 
such as monocyte chemo-attractant protein 1 (MCP-1 or 
CCL2)[66], IL-6, IL-8, soluble ICAM-1, Interferon gam-
ma-induced protein 10 (IP-10 or CXCL10) and MCP-2 
(or CCL8). The secretion of  these factors is dependent 
on inflammatory conditions and could enhance immune 
response via immune cell attraction[67]. Therefore, MSCs 
appear to have a dual immunomodulatory capacity de-
pending on the above-identified secreted factors. 
The mechanisms involved in the immunomodula-
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injection[88].
In fact, it is thought that MSCs are likely to act 
through the secretion of  soluble factors and change of  
the tissue microenvironment with paracrine interactions, 
rather than through their transdifferentiation capac-
ity[91,92]. However, current in vivo data are not sufficient to 
define the exact mechanism. It has been demonstrated 
that MSCs could facilitate tissue repair by stimulating an-
giogenesis[93] and inhibiting apoptosis, as well as fibrosis, 
in the site of  injury[94]. 
Furthermore, there is much evidence supporting the 
protective effect of  MSCs in acute kidney injury mod-
els[95]. It appears that MSCs could increase the prolifera-
tion of  tubular cells and reduce apoptosis[96,97]. There is a 
lack of  data on the treatment of  liver injury with MSCs, 
but their properties and regenerative potential mentioned 
above have encouraged researchers and clinicians to in-
vestigate further in this field. They could play a therapeu-
tic role in the replacement of  diseased hepatocytes, and 
the stimulation of  their regeneration through the action 
of  trophic molecules[98].
In a study on acute liver injury, rats were successfully 
treated with MSC infusion, with a decrease of  biochemi-
cal markers of  liver injury and an improved survival rate. 
Hepatocyte replication was enhanced while apoptosis 
decreased by 90%[98]. Similarly, it has been demonstrated 
that MSCs are efficient in treating fulminant hepatic fail-
ure in rats[99]. Otherwise, it has been suggested that MSCs 
could only be efficient in a therapeutic window, indicating 
that higher doses could paradoxically be inefficient or 
even induce liver fibrosis[98].
Although it is hoped that MSCs could potentially be 
an alternative to liver transplantation in end-stage liver 
disease, or a potential temporary solution to maintain-
ing liver conditions of  patients waiting for a graft, MSCs 
have been tried in only a small number of  clinical trials to 
treat cirrhosis.
In a phase Ⅰ-Ⅱ trial, 8 patients with end-stage liver 
cirrhosis were treated with the infusion of  autologous 
MSCs via a peripheral or portal vein. The treatment was 
well tolerated, with no significant adverse effects and the 
liver function was significantly improved[100]. A random-
ized placebo-controlled trial using MSCs to treat decom-
pensated cirrhosis has recently been published[101]. Out of  
27 patients, 15 received autologous bone marrow MSCs 
via a peripheral vein and 12 received a placebo. The re-
sults were evaluated using the Model for End-Stage Liver 
Disease (MELD) score, Child-Pugh score, liver function 
tests and liver volume. In this study, there was no benefi-
cial effect of  MSC infusion in cirrhotic patients. It is clear 
that other studies with larger cohorts are necessary to 
clarify the therapeutic potential of  MSCs in cirrhosis.
ANTI-OXIDATIVE EFFECT/TREATMENT 
OF ISCHEMIA REPERFUSION INJURY 
Ischemia reperfusion injury (IRI) is caused by the blood 
supply returning into a tissue after an ischemic period. 
tory capacity of  MSCs are complex and remain largely 
unknown. Their properties seem to be highly dependent 
on many parameters in which local immunologic condi-
tions seem to play a crucial role. Finally, it is important to 
know that there is currently no single standard method 
to isolate MSCs. It is thus conceivable that changes in the 
culture medium used to increase and select MSC popula-
tion may influence their properties. 
TISSUE REPAIR/“ORGAN 
RECONSTRUCTION” EFFECT 
In addition to their ability to differentiate into cells of  
the mesenchymal lineage, it has been demonstrated that 
MSCs can also differentiate in vitro into other cells such 
as neurons[68], cardiomyocytes[69], tubular epithelial cells 
in kidneys and hepatocytes[70-72]. They are also capable 
of  differentiating and engrafting into many tissues, espe-
cially if  an inflammatory signal is present[73]. These data 
have motivated further research in the field of  MSCs as 
potential “tissue repairers”. Cultured MSCs have shown 
strong evidence of  “tissue repair” properties in response 
to tissue injury or disease in many animal models with 
myocardial infarction[74], kidney disease[75,76], lung injury 
or some neurological disorders[64]. In clinical trials, MSCs 
have been used successfully to treat bone and cartilage 
diseases[77] (e.g., osteogenesis imperfecta), as well as acute 
and chronic myocardial infarction[78-80]. 
MSCs have shown the ability to home in on injured 
tissue after intravenous infusion. It has been demon-
strated that MSCs can express several chemokine recep-
tors such as CCR1, CCR7, CXCR4, CXCR6, CX3CR1[81], 
CCR4, CCR10, CXCR5[82], c-Kit, c-Met[83], VEGF recep-
tors[84] and PDGF receptors[85]. This variety of  recep-
tors and the chemotactic migration they have shown in 
response to the stimulating chemokines and cytokines 
could partially explain their ability to migrate to sites of  
inflammation. This hypothesis assumes that the injured 
tissue also expresses specific receptors facilitating the 
adhesion and migration of  MSCs. However, the exact 
mechanism of  homing in on injured tissue remains large-
ly unknown.
Nevertheless, many studies have observed that MSCs 
are significantly trapped in the lung after intravenous 
infusion[86,87]. Despite their ability to migrate to inflam-
mation sites and to differentiate into many tissues, MSCs 
exhibit very low and transient levels of  engraftment in 
vivo[86,88]. For example, in a mouse model of  acute myocar-
dial infarction, a significant improvement of  myocardial 
function was observed after human MSC injection, while 
no donor cell could be detected 3 wk after infusion. In a 
rat model, no MSC could be found in the liver within 7 
d after injection of  syngeneic rat MSCs in recipient livers 
through the portal vein[89]. Contradictorily, in a clinical 
trial treating myocardial infarction with intracoronary 
injection of  MSCs, the MSCs were still viable 3 mo after 
transplantation[90]. In another study, MSCs were detected 
in various tissues of  baboons 19 mo after intravenous 
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This sudden reperfusion and oxygenation paradoxically 
impairs the endothelium with a dilatation in arterioles, 
increased fluid filtration and plasma protein extravasa-
tion from post-capillary venules, as well as an increased 
production of  oxygen radicals and a reduction of  nitric 
oxide generation. This imbalance leads to the release of  
inflammatory mediators (e.g., TNF, platelet activating fac-
tor) and the expression of  adhesion molecules that cause 
leukocyte adhesion to the endothelium[102]. This results 
in the stimulation of  both innate and adaptive immune 
responses with an accumulation of  immune cells, fol-
lowed by organ damage. The release of  danger-associated 
molecular patterns (DAMPs) and the complement system 
are also implicated[103]. 
Solid organ transplantation is impacted by IRI, which 
contributes to acute graft rejection, delayed graft function 
and enhanced immunogenicity. IRI represents a major 
concern in liver transplantation, and use of  MSCs in IRI 
has been studied for solid organ transplantation in animal 
models and in clinical trials.
MSCs seem to be recruited by hypoxic and injured 
tissues that express adhesion molecules and a SDF-1 gra-
dient stimulating CXCR4 and CXCR7 on these cells[104]. 
Furthermore, it has been demonstrated that MSCs can 
transmigrate through TNF-alpha activated endothelium 
to join the inflamed tissue[105]. Lately, Pan et al[106] found 
that the inactivation of  the MEK/ERK signalling path-
way by MSCs plays a major role in the improvement of  
hepatic IRI in rats. 
Prevention and treatment of liver IRI in animal models
MSCs have shown therapeutic effects for the treatment 
of  IRI in the kidney, heart and lung in a significant num-
ber of  studies[107]. Only a few studies have been published 
for IRI in the liver, and the exact role of  MSCs has not 
yet been defined. 
Jin et al[108] recently evaluated the effect of  allogeneic 
bone marrow (BM)-derived MSCs to attenuate IRI in rats 
during the first 24 h after liver reperfusion. In their model 
partial ischemia was obtained by vascular clamping during 
60 min. BM-MSCs were injected through the portal vein. 
Injury severity, oxidative stress response and apoptosis 
of  the liver was regularly evaluated during the first 24 
h and compared to a sham-transplanted control group. 
The conclusion of  this study is that allogeneic BM-MSCs 
partially protect the liver from IRI when injected via the 
portal vein due to their ability to suppress oxidative stress 
and to inhibit apoptosis. Another related model using 
adipose-derived MSC injections via a peripheral vein in 
mice also showed a significant protective effect against 
liver IRI[109].
In addition to liver IRI, research has also focused on 
the potential beneficial effect of  MSCs in partial liver 
transplantation. In a recent study 50% reduced-size liver 
transplantations in rats were used to examine whether 
MSC-conditioned medium (MSC-CM) could protect he-
patocytes and sinusoidal endothelial cells (SEC) and en-
hance their regeneration[110]. MSC-CM was injected in rats 
via a peripheral vein directly after orthotopic partial liver 
transplantation. Compared with the control group, the 
MSC-CM group showed a significantly lower release of  
liver injury biomarkers and a clear survival benefit. More 
proliferating hepatocytes and SECs, and less apoptosis 
were observed. Many inflammatory cytokine levels and 
the infiltration by neutrophils and Kupffer cell activa-
tion were decreased. VEGF and MMP-9 expression was 
increased in the graft. All these facts suggest that MSC-
CM could have potential in prevention of  liver injury, 
and to enhance its regeneration in partial liver transplant. 
Kanazawa et al[111] also found in a model of  IRI with ma-
jor hepatectomy that MSCs protected the liver from IRI 
and that liver regeneration was enhanced. 
However, it has been demonstrated in a liver IRI 
model that intravenously injected MSCs are short-lived, 
that viable MSCs do not go beyond the lungs, and that 
they remain in the circulation for a very limited period[112]. 
It has thus been suggested that other cells should be im-
plicated to mediate the powerful immunomodulatory and 
regenerative properties of  MSCs on target organs. 
POTENTIAL USE OF MSCS IN LIVER 
TRANSPLANTATION
Liver transplantation represents the unavoidable treat-
ment of  end-stage liver diseases. Despite satisfactory 
long-term results, transplantation success mostly relies 
on immunotolerance, via acceptable graft-host immune 
matches and immunosuppressive measures. The latter 
unfortunately exposes the patient to the classical con-
sequences of  a down-regulated immune system, such 
as opportunistic infections and the typical outbreak of  
neoplasms. Due to their immunomodulatory properties, 
MSCs could prove highly effective in obtaining sufficient 
immunotolerance to reach even higher success rates while 
avoiding excessive immunosuppression, and thus severe 
and life-threatening side effects.
MSCs as immunomodulation therapy in transplantation
MSCs for graft-vs -host disease after hematopoietic 
cell transplantation: A clinical success? Graft-vs-host 
disease (GVHD) is a major complication frequently ob-
served after hematopoietic cell transplantation (HCT), 
resulting from the attack of  recipient organs by donor 
lymphocytes. MSCs might play a role in the treatment of  
GVHD through their immunomodulatory effects rather 
than their regenerative properties. Although pre-clinical 
studies for the prevention or treatment of  GVHD by 
MSCs gave rise to conflicting results, MSCs have shown 
a clear efficacy in clinical trials, especially in steroid-
resistant GVHD[113]. In a phase Ⅱ study, 68% of  patients 
with acute steroid-resistant GVHD showed a complete 
response to MSC infusion with a significant decrease in 
mortality[114]. A series of  other studies have shown similar 
results with varying degrees of  GVHD, suggesting that 
MSCs have a serious potential future in GVHD manage-
ment[115-117]. 
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MSCs in solid-organ transplantation
Animal models: MSC infusion has shown the ability 
to prolong graft survival in heart[118-120], skin[121] and kid-
ney[122-124] animal transplantation models. However, one 
group found no effect of  MSCs alone on heart allograft 
survival in a mouse model[125], and another group found 
that MSCs infused after kidney transplantation could 
cause premature graft dysfunction[122]. 
Only a few studies have been published in liver 
transplantation models. In one such study, it was demon-
strated that adipose-derived MSCs significantly decreased 
acute rejection after orthotopic liver transplantation in 
rats[126], based on serum rejection markers and on hepa-
tocyte apoptosis. Serum levels of  IL-2 were reduced and 
those of  IL-10 were increased. In this model, MSC were 
infused intravenously 7 d before and 3 d after liver trans-
plantation as well as during the operation via the portal 
vein. MSCs also played a role in a discordant liver xeno-
transplant model by alleviating acute rejection[127].
Another group studied the ability of  BM-MSC infu-
sion to inhibit acute graft rejection after allogeneic liver 
transplantation in rats[128]. MSCs were derived from the 
recipient, the liver donor or a third party, and infused 
intravenously at the time of  surgery as well as once daily 
for 3 d thereafter. MSC-treated recipients survived sig-
nificantly longer compared with the control group. Fur-
thermore, there was no significant difference between the 
3 groups receiving MSCs from various origins. Histologi-
cal analysis showed severe acute graft rejection at day 7 
in rats without MSC infusion, while acute graft rejection 
was significantly decreased in the other groups. These 
observations were associated with a marked increase in 
the number of  T-reg cells in recipients receiving MSCs. 
This suggests an important role of  T-reg cells in MSC-
mediated immunosuppression. 
Available data in humans (kidney transplantation)
Results of  a phase Ⅰ clinical trial studying the treatment 
of  allograft rejection after kidney transplantation by au-
tologous BM-MSCs, have recently been published[129]. 
The MSC-based treatment was well-tolerated and no 
related serious adverse effects were reported. Two MSC 
infusions were performed after a biopsy-proven rejec-
tion or interstitial fibrosis/tubular atrophy (IF/TA). In 
this study, MSCs showed their ability to reduce IF/TA. 
In addition, a donor-specific down-regulation of  the pe-
ripheral blood mononuclear cell proliferation was shown. 
However, a potentially increased susceptibility to oppor-
tunistic infections was observed, with the development 
of  viral infections in 3 out of  6 MSC-treated patients.
In a randomized controlled trial in living donor kid-
ney transplantation, Tan et al[130] demonstrated that, in 
comparison with antibody induction therapy, induction 
by autologous MSCs significantly correlated with fewer 
acute rejections, a lower risk of  opportunistic infec-
tions and a better renal function at 1 mo. Furthermore, 
fewer adverse effects were seen in both autologous MSC 
groups compared to the control group. This study was 
conducted on 156 patients recruited from February 2008 
to May 2009 and divided into 3 groups (group 1 and 2 
received MSCs at kidney reperfusion and two weeks later, 
plus a standard dose or low dose of  calcineurin inhibitors 
(CNIs), respectively. The control group received anti-IL-2 
receptor antibody plus standard-dose CNIs. 
In a pilot study, Perico et al[131] injected autologous 
BM-MSC in 2 living-related kidney transplant recipients 
at day 7 post-transplant, after induction therapy with basi-
liximab/low-dose thymoglobulin. The peripheral blood 
showed a progressive increase of  the T-reg population 
and a strong inhibition of  memory/effector CD8 T cell 
function/expansion, promoting a long-term tolerogenic 
environment compared with the control group. However, 
a few days after MSC infusion transient renal dysfunction 
was observed. A biopsy excluded graft rejection but re-
vealed a focal inflammatory infiltrate with neutrophil and 
MSC recruitment as well as a complement-C3 deposition. 
The same group also investigated pre-transplant infu-
sion of  autologous BM-MSCs in 2 living-related kidney 
transplant recipients[132]. No renal dysfunction was ob-
served while MSC immunomodulatory properties were 
preserved. In addition, it was observed that the avoidance 
of  basiliximab in induction therapy did not facilitate fur-
ther T-reg expansion. 
In another recent pilot study, six patients transplanted 
with living-donor related kidneys received 2 donor-
derived BM-MSC infusions (the first at the time of  trans-
plantation, the second one month later) in combination 
with sparing doses of  tacrolimus[133]. Six other patients 
were used as a control group and received standard doses 
of  tacrolimus and no MSCs. The MSC-treated group 
had stable renal function 12 mo post-transplant despite 
reduced tacrolimus compared with the control group. No 
acute rejection occurred, except for one in the control 
group. Significantly increased B cell levels were observed 
in the MSC-treated group 3 mo after transplantation. No 
toxic side effects were associated with MSC infusion. 
Ongoing clinical trials in liver transplantation
MSC Liege study: Taking advantage of  our expertise 
and experience concerning the use of  MSCs in the HCT 
context[115], and using an already functioning good manu-
facturing practice (GMP)-compliant laboratory able to 
produce clinical-grade MSCs, we initiated a first trial in 
2011 exploring the safety and tolerability of  third-party 
MSC infusions after kidney or liver transplantation in a 
prospective phase Ⅰ-Ⅱ study (NCT01429038). 
In this study, after successful transplantation, 10 liver 
and 10 kidney transplant recipients under standard im-
munosuppressive treatment (tacrolimus, mycophenolate 
mofetil (MMF) and steroids) receive an intravenous infu-
sion of  1.5 × 106/kg-3 × 106/kg of  third-party MSCs on 
post-operative day 3 ± 2. These patients are prospectively 
compared to the same number of  liver or kidney trans-
plant recipients who meet inclusion criteria but have not 
not received MSC infusion. Safety is assessed by record-
ing side effects, including opportunistic infections and 
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cancers. The immunosuppressive potential of  MSCs will 
be evaluated by the rate of  rejection episodes, graft/pa-
tient survivals, immunohistology of  3-mo (kidney) and 
6-mo (liver) graft biopsies and in vitro evaluation of  pa-
tient immune functions. In a second step, reduction (kid-
ney) and progressive weaning (liver) of  immunosuppres-
sion will be attempted in recipients who received MSCs. 
Final results are expected by the end of  2014. The next 
step will be to assert the immunosuppressive potential of  
MSCs after organ transplantation, and the opportunity to 
develop larger, randomised and controlled phase Ⅲ trials.
“Mesenchymal stem cells in solid organ transplan-
tation”-1 study: In a mesenchymal stem cells in solid 
organ transplantation phase Ⅰ study (MiSOT-I) started 
in April 2013, the safety of  MultiStem® infusion for im-
munomodulation after liver transplantation has been 
evaluated (NCT01841632). MultiStem is a new biological 
product derived from multipotent adult progenitor cells 
(MAPCs) which belong to the family of  MSCs. Patients, 
divided into four cohorts, will receive 2 doses of  Multi-
Stem (first intraportal at liver transplantation, second at 
day 3 post-transplant) in addition to immunosuppression 
(calcineurin-inhibitor-free ‘bottom-up’ immunosup-
pressive regimen with basiliximab, mycophenolic acid, 
and steroids). From cohort 1 to 4, an increasing dose 
escalation is performed (3-6 patients in each group). The 
primary outcome will be infusional and acute toxicity 
(intraportal, pulmonary and systemic). The secondary 
outcomes will be biopsy-proven acute rejection, whether 
MultiStem promotes malignant transformationnor tumor 
growth, and the long-term safety of  MultiStem adminis-
tration (up to 6 years). Final results are expected in 2016.
The Beijing study
A third study is ongoing. This phase Ⅰ study will include 
a total of  50 patients randomly assigned to two groups; 
in the first group, patients will receive conventional im-
munosuppressive agents plus umbilical cord (UC-) MSCs 
at the day of  liver transplantation and then once every 
4 wk, at a dose of  1 × 106 UC-MSCs/kg for 12 wk 
(NCT01690247). In the second group patients will re-
ceive conventional treatment plus a placebo. Both groups 
will be followed for 48 wk. The study will evaluate the 
incidence of  acute rejection and early liver function re-
covery, as well as patient and graft survival rates, and the 
prevalence of  adverse events as secondary outcomes.
VARIABLES TO BE CONSIDERED/ISSUES 
TO BE RESOLVED
At present many questions remain unanswered in the 
field of  MSCs therapy in solid-organ transplantation. 
These issues could explain the conflicting data obtained 
in previous studies. Further in vitro investigations and 
pre-clinical studies could help to define the settings of  
future clinical trials through a better understanding of  the 
mechanisms of  action of  MSCs.
Dosage and sources of MSCs 
The ideal amount of  MSCs necessary to achieve some 
clinical effect has not yet been studied, and additionally, 
the ideal source of  MSCs in the setting of  organ trans-
plantation has not been determined. Usually isolated 
from the bone marrow, MSCs can now be isolated from 
other more easily accessible human tissues such as adi-
pose tissue or cord-blood. Compared with BM-derived 
MSCs, adipose- and cord- derived MSCs have compa-
rable phenotypical and immunomodulatory properties[134]. 
Nevertheless, it seems that many genes are differentially 
expressed in MSCs depending on their tissue origin[135]. 
These differences could alter the function of  MSCs in 
clinical use.
Although not quite clear, it should be noted that 
MSCs derived from adipose tissue seem to be more likely 
to develop chromosomal abnormalities than BM-derived 
MSCs, after many passages in culture[136,137]. High-passage 
MSCs should thus be avoided for clinical applications.
Origin of MSCs- autologous vs allogeneic
MSCs can be isolated from the organ recipient (autolo-
gous) or from the organ donor, or from a third party (al-
logeneic). 
While some have suggested that allogeneic MSCs 
may be more efficient as immunosuppressors[138], others 
have shown in animal models that donor-derived MSCs 
could be preferable[139]. In a recent study, it has been 
demonstrated that both autologous and allogeneic MSCs 
were able to inhibit alloreactivity and had comparable ef-
ficacy[22,127].
In terms of  alloreactivity, MSCs appear to bear low 
immunogenicity (see above). In a clinical case of  osteo-
genesis imperfecta, no sign of  alloreactivity was observed 
in the recipient after infusion of  fully mismatched alloge-
neic MSCs[140]. Yet some papers have reported the induc-
tion of  memory T cell responses and immune rejection 
after allogeneic MSC infusion[18,141]. One cannot exclude 
that donor-derived MSCs could induce alloreactivity and 
accelerate graft rejection. Nevertheless, in the field of  
kidney transplantation, Crop et al[22] have demonstrated 
that donor-derived MSCs are not immune-rejected and 
are even able to inhibit alloreactivity in kidney transplant 
patients when infused before transplantation.
MSC interaction with immunosuppressive drugs 
In clinical transplant studies, MSCs are used concomi-
tantly with immunosuppressive drugs. As MSCs and 
immunosuppressive drugs inhibit the same targets (es-
sentially T cells), it is reasonable to consider that interac-
tions between them can occur. Therefore, it is essential 
to know which drugs can (positively or negatively) affect 
MSC function.
In vitro, some have shown that tacrolimus (a calcineu-
rin inhibitor) and rapamycin (a mTOR inhibitor) decrease 
MSCs immunosuppressive properties[142], and conversely, 
that MSCs reduce the immunosuppressive capacities of  
tacrolimus and rapamycin. Such an effect has not been 
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found with mycophenolic acid (MPA). Moreover, a high 
dose of  tacrolimus seems to be toxic for MSCs, while 
MPA and rapamycin at a therapeutic dose just inhibit 
MSC proliferation[143]. Nevertheless, others have shown 
that cyclosporine A (CsA) (another calcineurin inhibitor) 
and MSCs exert cumulative effects against alloactivated 
lymphocytes[138]. Furthermore, it has been demonstrated 
that MPA and MSCs have a synergistic immunosuppres-
sive effect[143]. 
In vivo, MPA and MSCs also synergize to promote 
long-term allograft tolerance in rat heart transplanta-
tion[144]. In contrast to what is observed in vitro, rapamycin 
and MSCs synergize as immunomodulators to promote 
cardiac allograft long-term survival[119]. Moreover, in a rat 
renal transplantation model, it has been shown that CsA 
antagonizes MSC efficacy, and that this combination has 
no advantage in terms of  allograft survival rates com-
pared with CsA alone[122]. Nevertheless, this study has to 
be contrasted with other studies using various immuno-
suppressive drug used together with CsA in which MSC 
efficacy was not altered[19,110]. The choice of  concomitant 
immunosuppressive drugs is an important matter for de-
bate, and more studies are needed to define which are the 
most effective drugs to use with MSCs. 
Timing of administration of MSCs
MSCs can be injected before, during or after transplanta-
tion, and with single or repeated injection(s). Timing of  
administration is another important point for discussion. 
It has been shown in vivo that pre-transplant infusion 
could be more effective than peri-transplant infusion in 
preventing graft rejection in a murine heart transplan-
tation model[120]. On the other hand, it has been dem-
onstrated that MSCs are effective in the treatment of  
steroid-resistant GVHD[113], so at the peak of  the disease. 
In a clinical trial, Perico et al[131] observed that early post-
transplant infusion of  MSCs could induce a transient 
renal dysfunction. This group is now investigating pre-
transplant infusions[132]. 
Protocols investigating timings of  administration 
will probably have to be defined according to expected 
effects and drugs used concomitantly. Regarding liver 
transplantation, our group infuses MSCs at day 3 post-
liver transplantation, while the MiSOT group performs 2 
injections of  MSCs at day 0 (intra operatively) and day 3 
post-transplantation. In the Beijing study, an injection is 
performed on the day of  liver transplantation and then 
once every 4 wk during a 12-wk period.
Administration route
In case of  liver transplantation, MSCs can be injected 
through a peripheral vein or through intraportal infusion 
during surgery, or a combination of  both. Intraportal 
infusion could be helpful in increasing the amount of  
MSCs homing to the liver. On the other hand, MSC 
homing behaviour to the inflammation site[69] could po-
tentially concentrate them in the liver when intravenously 
infused after hepatic transplantation. However, some 
studies have observed that MSCs could be trapped in the 
lung after intravenous infusion[86,87]. Whatever the case, 
it is clear that to define the best route of  administration, 
it is necessary to better understand the homing capacity 
of  MSCs, and whether MSCs really require close contact 
with the target organ in order to be effective. 
MSC side effects and safety
To date, no major adverse effects have been reported in 
the mid-term in the significant number of  clinical trials 
using MSC-based therapy, for example in the context 
of  BMT[113-117], solid-organ transplantation[129-133] and in 
many completed clinical trials for various therapeutic ap-
plications[145]. Only some studies have shown mild and 
transient adverse effects around the time of  injection[145]. 
More experience is needed in order to confirm the long-
term safety of  MSCs.
To reach a sufficient number of  cells for MSC-based 
therapy, in vitro expansion is needed. In this context, one 
of  the major concerns is the potential risk of  a neoplastic 
transformation of  MSCs[122]. The occurrence of  chromo-
somal aberrations is not uncommon after in vitro culture 
of  mMSC, especially after long-term culture. It has been 
shown in vivo that these chromosomally unstable cells 
could transform into malignant cells with generation of  
tumors in vivo[146-148].
Contrary to mMSCs, in vitro expansion of  hMSC 
seems to be far more stable and does not seem to gen-
erate genomic instability in these cells even after long-
term culture. They do not transform into malignant cells 
after transplantation in mice[149,150]. Nevertheless, a French 
study observed the occurrence in vitro of  transient chro-
mosomal aberrations (aneuploidy) in twenty preparations 
of  BM-MSCs obtained under GMP with two different 
culture processes. However these cells showed the same 
senescence as “normal” MSCs and did not lead to tu-
moral process after injection in immunocompromised 
mice[151]. Another study has found a high rate of  human 
MSCs spontaneously transformed in malignant cells in 
vivo[152] but this has been strongly controverted suggesting 
a cross-contamination with cancerous cells[153]. Moreover, 
in two recent reviews analysing numerous studies, no evi-
dence was found to affirm the potential of  human MSCs 
for malignant transformation and so far, no risk of  ma-
lignant transformation has been found in clinical use of  
hMSCs[149,154]. 
As MSCs are used as immunosuppressors, another 
concern is the potential emergence of  opportunistic in-
fections and induced cancers. In the case of  solid organ 
transplantation with MSC-based immunosuppression, no 
increase risk of  viral opportunistic infections has been 
observed so far-one group having even observed a de-
crease[130]. Nevertheless, another group reported viral op-
portunistic infections in three patients[129]. 
Interestingly, the MiSOT study group recently estab-
lished a system to objectively score the potential emerg-
ing adverse effects related to MSC infusions (intravenous 
or intraportal infusion) after liver transplantation[155]. This 
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score is calculated using three parameters (pulmonary 
toxicity, intraportal-infusional toxicity and systemic tox-
icity), each of  them receiving a score of  0 (no adverse 
events) to 3 (severe adverse events). It has been retro-
spectively validated on a cohort of  187 liver-transplanted 
patients not receiving MSCs as a control population. It 
has been suggested that this new tool could be helpful in 
assessing the safety of  MSC use in solid organ transplan-
tation. 
CONCLUSION
The accumulating evidence shows that MSCs have im-
munosuppressive and reparative capacities in vivo and in 
vitro, as well as a potential beneficial effect in ischemia-re-
perfusion injury. These three principal properties suggest 
that MSCs could be interesting in liver transplantation to 
prevent or treat IRI, allograft dysfunction and graft rejec-
tion by inducing a durable tolerogenic environment. Us-
ing MSCs, and thereby removing or reducing the need for 
immunosuppressive drugs could avoid the serious side 
effects associated with these drugs.
Currently available data in clinic show that MSCs are 
safe to use, at least in the medium-term, but more time 
is needed to evaluate their potential adverse effects on 
the long-term. Caution is therefore recommended. Even 
if  encouraging, the results of  MSC use in vitro and in vivo 
(animals and humans) are sometimes contradictory. Nev-
ertheless, negative results do not necessarily mean that 
MSCs are not effective in solid-organ transplantation, but 
rather that a countless number of  still unknown (or poor-
ly known) parameters may influence their effectiveness. 
At the same time, many issues must be resolved to opti-
mize their use. Intensive in vitro and pre-clinical research 
is certainly the key to a better understanding of  the way 
that MSCs act, and to eventually lead to clinical success.
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